The metabolic syndrome in hypertension: Diagnostic and therapeutic implications

被引:0
|
作者
Josep Redon
Renata Cífková
机构
[1] University of Valencia,Hypertension Clinic, Internal Medicine, Hospital Clinico
来源
关键词
Metabolic Syndrome; Carvedilol; Valsartan; Impaired Fasting Glucose; Telmisartan;
D O I
暂无
中图分类号
学科分类号
摘要
Arterial hypertension is often part of a larger constellation of anthropometric and metabolic abnormalities that includes abdominal (or visceral) obesity, characteristic dyslipidemia (low high-density lipoprotein cholesterol and high triglyceride levels), glucose intolerance, insulin resistance, and hyperuricemia. Using National Cholesterol Education Program Adult Treatment Panel III criteria, prevalence is higher than in the general population and the metabolic syndrome can be found in as many as one third of patients. Among hypertensives with metabolic syndrome, a high prevalence of hypertension-induced target-organ damage and a poor prognostic value has been described. Dietary advice and lifestyle changes should be strongly recommended and prompt pharmacologic treatment is required to control high blood pressure and to reduce risk. The impact of particular antihypertensive drugs on other components of the metabolic syndrome is an important clinical issue with consequences for the success of treatment.
引用
收藏
相关论文
共 50 条
  • [11] Psoriasis and Metabolic Syndrome: Comorbidities and Environmental and Therapeutic Implications
    Peralta, Cesar
    Hamid, Pousette
    Batool, Humera
    Al Achkar, Zeina
    Maximus, Pierre
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)
  • [12] THERAPEUTIC EFFICACY OF QUERCETIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
    Bilovol, O. M.
    Kniazkova, I. I.
    Kuzminova, N., V
    Kirienko, O. M.
    Abramova, L. P.
    Gavrylyuk, A. O.
    WORLD OF MEDICINE AND BIOLOGY, 2021, 75 (01): : 18 - 22
  • [13] Brain natriuretic peptide: Diagnostic and therapeutic implications in pulmonary arterial hypertension
    Hargett, CW
    Tapson, VF
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (04) : 385 - 393
  • [14] Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials
    Amgad N. Makaryus
    Philippe Akhrass
    Samy I. McFarlane
    Current Diabetes Reports, 2009, 9
  • [15] Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials
    Makaryus, Amgad N.
    Akhrass, Philippe
    McFarlane, Samy I.
    CURRENT DIABETES REPORTS, 2009, 9 (03) : 229 - 237
  • [16] Hypertension and triglyceride catabolism: Implications for the hemodynamic model of the metabolic syndrome
    Brook, RD
    Glazewski, L
    Rajagopalan, S
    Bard, RL
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2003, 22 (04) : 290 - 295
  • [17] MENACE SYNDROME IN ANTERIOR DESCENDING ARTERY - DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS
    NEIMANN, JL
    CUILLIERE, M
    PAQUIS, M
    MATHIEU, P
    CHERRIER, F
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1975, 68 (11): : 1123 - 1131
  • [18] Frontal syndrome in schizophrenia and frontotemporal dementia: diagnostic and therapeutic implications
    Jaracz, Jan
    Rybakowski, Janusz
    NEUROPSYCHIATRIA I NEUROPSYCHOLOGIA, 2011, 6 (01): : 18 - 24
  • [19] The polycystic ovary syndrome - Pathogenesis, metabolic implications, and therapeutic approach
    DiamantiKandarakis, E
    ADOLESCENT GYNECOLOGY AND ENDOCRINOLOGY: BASIC AND CLINICAL ASPECTS, 1997, 816 : 177 - 193
  • [20] BUDD-CHIARI SYNDROME IN THE CONTEXT OF ANTIPHOSPHOLIPID SYNDROME - DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS
    ARCHIMANDRITIS, A
    CHRISTOPOULOU, V
    TSIRANTONAKI, M
    VLACHOYIANNOPOULOS, P
    ZAVOS, G
    ARONI, K
    LUPUS, 1995, 4 (04) : 329 - 331